High Blood Pressure has become a major public health concern in recent times. Research into natural remedies for health ...

Neurocrine Biosciences begins phase 3 registrational study of osavampator as an adjunctive therapy to treat major depressive disorder: San Diego Wednesday, January 29, 2025, 18:00 ...

GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the drug off the US market.

Takeda has named Julie Kim as its next CEO. She will replace Christophe Weber who plans to step down in June of 2026 after leading Japan’s largest drugmaker for 11 years. The company called the ...

Tokyo, Jan. 30 (Jiji Press)--Japan's Takeda Pharmaceutical Co. said Thursday that its president and CEO, Christophe Weber, will step down at its general shareholders meeting in June 2026.

Julie Kim is set to replace Christophe Weber as the new chief executive officer of Takeda Pharmaceutical Co., becoming the first woman to lead the more than 240-year-old Japanese drugmaker.

Julie Kim is set to replace Christophe Weber as the new CEO of Takeda Pharmaceutical, becoming the first woman to lead the more than 240-year-old Japanese drugmaker. Kim, 54, has been running ...

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance last spring.

Takeda Canada Inc. (Takeda ... who have been previously treated with or are not considered candidates for available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan ...

Takeda Pharmaceutical said on Thursday its CEO Christophe Weber will retire after more than a decade at the helm of Japan's biggest drugmaker as the company upped its full-year profit outlook. Julie ...

Takeda(TOKYO:4502/NYSE:TAK) announced today that its Board of Directors made the decision unanimously to appoint Julie Kim, currently president of Takeda’s U.S. Business Unit, as the successor to ...